Загрузка компании
Just reported
Q3 2026 results
From Neuropace's results release of 12 ноября 2026 г.. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
23,1M $
-16 % y/y
+1,2 % q/qGuided
—
No guide given
Operating income, adjusted
Actual
400K $
Guided
—
No guide given
Company outlook
Full year 2026
- Revenue91M $ – 92M $-8,5 % y/y Lowered -9,0 %
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Neuropace is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc131,6B $A+
SYKStryker Corp.117,9B $A+
EWEdwards Lifesciences Corporation61,6B $A+
GEHCGE Healthcare Technologies Inc.37,5B $A
GKOSGlaukos Corp14,5B $A
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 окт. 2026 г.CBGraded C, now B
MCKMckesson Corporation4 нояб. 2026 г.BAGraded B, now A
CVSCVS Health Corp4 нояб. 2026 г.BAGraded B, now A- EWEdwards Lifesciences Corporation4 нояб. 2026 г.BAGraded B, now A
- GEHCGE Healthcare Technologies Inc.28 окт. 2026 г.CAGraded C, now A
Полная финансовая отчётность →
Построено по собственной отчётности Neuropace, Inc., поданной в Комиссию по ценным бумагам и биржам США (SEC). Цифры — как отчиталась компания, история на акцию пересчитана на сегодняшнюю базу. Это описание бизнеса — не инвестиционная рекомендация и не совет что-либо покупать или продавать.
